2019 Expert opinion on biological treatment use in inflammatory bowel disease management.
作者信息
Törüner Murat, Akpınar Hale, Akyüz Filiz, Dağlı Ülkü, Över Hamzaoğlu Hülya, Tezel Ahmet, Ünsal Belkıs, Yıldırım Süleyman, Çelik Aykut Ferhat
机构信息
Department of Gastroenterology, Ankara University School of Medicine, Ankara, Turkey.
Department of Gastroenterology, Dokuz Eylül University School of Medicine, İzmir, Turkey.
出版信息
Turk J Gastroenterol. 2019 Nov;30(Suppl 4):S913-S946. doi: 10.5152/tjg.2019.061119.
Abstract
摘要
相似文献
1
2019 Expert opinion on biological treatment use in inflammatory bowel disease management.2019年关于生物治疗在炎症性肠病管理中应用的专家意见。
Turk J Gastroenterol. 2019 Nov;30(Suppl 4):S913-S946. doi: 10.5152/tjg.2019.061119.
2
Medical Management of Inflammatory Bowel Disease.炎症性肠病的医学管理。
Surg Clin North Am. 2024 Jun;104(3):657-671. doi: 10.1016/j.suc.2023.12.005. Epub 2024 Jan 3.
3
The role of biologics in the treatment of patients with inflammatory bowel disease.生物制剂在炎症性肠病患者治疗中的作用。
Br J Hosp Med (Lond). 2018 Dec 2;79(12):686-693. doi: 10.12968/hmed.2018.79.12.686.
4
Guidelines for the management of inflammatory bowel disease in adults.成人炎症性肠病管理指南。
Gut. 2004 Sep;53 Suppl 5(Suppl 5):V1-16. doi: 10.1136/gut.2004.043372.
5
[Chronic inflammatory bowel diseases: drug therapy standards and trends].[慢性炎症性肠病：药物治疗标准与趋势]
Internist (Berl). 2001 Apr;42(4):533-8, 540-3. doi: 10.1007/s001080050788.
6
Methotrexate for inflammatory bowel disease: time for reconsideration.甲氨蝶呤用于炎症性肠病：是时候重新考虑了。
Expert Rev Gastroenterol Hepatol. 2019 May;13(5):407-409. doi: 10.1080/17474124.2019.1596797. Epub 2019 Mar 21.
7
The role of integrin antagonists in the treatment of inflammatory bowel disease.整合素拮抗剂在炎症性肠病治疗中的作用。
Expert Opin Biol Ther. 2014 Dec;14(12):1815-23. doi: 10.1517/14712598.2014.967209. Epub 2014 Oct 7.
8
Disease-modifying anti-inflammatory bowel disease drugs (DMAIDs): the missing term in the literature.改善病情的抗炎性肠病药物（DMAIDs）：文献中缺失的术语。
Am J Gastroenterol. 2013 May;108(5):859-60. doi: 10.1038/ajg.2013.53.
9
Impact of COVID-19 pandemic on the management of paediatric inflammatory bowel disease: An Italian multicentre study on behalf of the SIGENP IBD Group.COVID-19 大流行对小儿炎症性肠病管理的影响：代表 SIGENP IBD 小组的意大利多中心研究。
Dig Liver Dis. 2021 Mar;53(3):283-288. doi: 10.1016/j.dld.2020.12.011. Epub 2020 Dec 26.
10
Proper Use of Inflammatory Bowel Disease Drugs during Pregnancy.孕期炎症性肠病药物的正确使用。
Dig Dis. 2016;34 Suppl 1(Suppl 1):61-6. doi: 10.1159/000447377. Epub 2016 Aug 22.
引用本文的文献
1
Factors affecting the development of complications in Crohn's disease in patients undergoing intestinal resection.影响接受肠切除术的克罗恩病患者并发症发展的因素。
Medicine (Baltimore). 2023 Feb 22;102(8):e32957. doi: 10.1097/MD.0000000000032957.
2
Perception of COVID-19 Pandemic Among IBD Clinicians and IBD Surgeons in Black Sea Region: A Cross-Sectional Questionnaire Study.《黑海水域炎症性肠病临床医生和外科医生对 COVID-19 大流行的认知：一项横断面问卷调查研究》
Turk J Gastroenterol. 2022 Dec;33(12):1004-1011. doi: 10.5152/tjg.2022.22009.
3
Turkish IBD Organization's Position Statement on Inflammatory Bowel Disease Management Recommendations During COVID-19 Pandemic.土耳其 IBD 组织关于 COVID-19 大流行期间炎症性肠病管理建议的立场声明。
Turk J Gastroenterol. 2021 Jun;32(6):488-492. doi: 10.5152/tjg.2021.280721.
4
Secukinumab-Induced Inflammatory Bowel Disease in a Patient Treated for Chronic Plaque Psoriasis and Psoriatic Arthritis: A Case Report and Review of the Role of Novel Biologic Agents Targeting the p19 Subunit of IL-23.司库奇尤单抗治疗慢性斑块状银屑病和银屑病关节炎患者引发炎症性肠病：一例报告及靶向白细胞介素-23 p19亚基新型生物制剂作用的综述
Case Rep Med. 2020 Jul 24;2020:9404505. doi: 10.1155/2020/9404505. eCollection 2020.
本文引用的文献
1
British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.英国胃肠病学会成人炎症性肠病管理共识指南。
Gut. 2019 Dec;68(Suppl 3):s1-s106. doi: 10.1136/gutjnl-2019-318484. Epub 2019 Sep 27.
2
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.维得利珠单抗与阿达木单抗治疗中重度溃疡性结肠炎的疗效比较。
N Engl J Med. 2019 Sep 26;381(13):1215-1226. doi: 10.1056/NEJMoa1905725.
3
ACG Clinical Guideline: Ulcerative Colitis in Adults.ACG 临床指南：成人溃疡性结肠炎。
Am J Gastroenterol. 2019 Mar;114(3):384-413. doi: 10.14309/ajg.0000000000000152.
4
Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab.在接受英夫利昔单抗维持治疗的炎症性肠病患者中，英夫利昔单抗谷浓度随时间推移而下降。
Eur J Gastroenterol Hepatol. 2019 Feb;31(2):187-191. doi: 10.1097/MEG.0000000000001332.
5
Targeting IL-23 in Crohn's disease.靶向治疗克罗恩病中的白细胞介素-23。
Expert Rev Clin Immunol. 2018 Nov;14(11):907-913. doi: 10.1080/1744666X.2018.1524754. Epub 2018 Sep 24.
6
A Practical Approach to the Use of Conventional Synthetic, Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for the Treatment of Inflammatory Arthritis in Patients with a History of Malignancy.常规合成、生物制剂和靶向合成疾病修饰抗风湿药物治疗有恶性肿瘤病史的炎症性关节炎患者的实用方法。
Curr Rheumatol Rep. 2018 Sep 1;20(10):64. doi: 10.1007/s11926-018-0774-9.
7
The characteristics of nivolumab-induced colitis: an evaluation of three cases and a literature review.纳武单抗诱导的结肠炎的特征：三例病例评估及文献综述
BMC Gastroenterol. 2018 Aug 31;18(1):135. doi: 10.1186/s12876-018-0864-1.
8
Tumor Necrosis Factor Inhibitors and Cancer Recurrence in Swedish Patients With Rheumatoid Arthritis: A Nationwide Population-Based Cohort Study.肿瘤坏死因子抑制剂与瑞典类风湿关节炎患者的癌症复发：一项全国范围内基于人群的队列研究。
Ann Intern Med. 2018 Sep 4;169(5):291-299. doi: 10.7326/M17-2812. Epub 2018 Aug 14.
9
Ustekinumab exposure during conception and pregnancy in patients with chronic plaque psoriasis: a case series of 10 pregnancies.慢性斑块状银屑病患者在受孕和孕期使用优特克单抗的情况：10例妊娠病例系列
Br J Dermatol. 2019 Jan;180(1):195-196. doi: 10.1111/bjd.17086. Epub 2018 Oct 4.
10
JAK inhibitors: Novel developments in management of ulcerative colitis.JAK 抑制剂：溃疡性结肠炎治疗的新进展。
Best Pract Res Clin Gastroenterol. 2018 Feb-Apr;32-33:89-93. doi: 10.1016/j.bpg.2018.05.015. Epub 2018 May 23.
Zotero 插件